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Abstract
Objective: Little is known about factors associated with suboptimal antiretroviral treatment (ART)
adherence among adolescents in Sub-Saharan Africa. Our objective was to determine the level of ART
adherence and predictors of non-adherence among human immunodeficiency virus (HIV)-infected
adolescents at the Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana.
Methods: In a cross-sectional study, 82 HIV-infected adolescents receiving ART and their caregivers were
administered a structured questionnaire. The patient's clinical information was retrieved from medical
records. Outcome measures included excellent pill count ART adherence (>95%) and virologic suppression
(HIV viral load <400 copies>/mL). Multivariate logistic regression analysis was performed to identify
independent predictors of ART non-adherence.
Results: The overall median (interquartile range) ART adherence was 99% (96.5–100) (N = 82). Seventy-six
percent of adolescents had excellent pill count ART adherence levels and 94% achieved virologic suppression.
Male adolescents made up 65% of the non-adherent group (P = 0.02). Those who displayed suboptimal ART
adherence were more likely to report having ever missed ART doses due to failure to pick up medication at
the pharmacy (30.0% versus 9.7%, P = 0.03). In the multivariate logistic regression model, male sex (odds
ratio [OR] 3.29, 95% confidence interval [CI] 1.13–9.54; P = 0.03) was the only factor which was
independently associated with suboptimal ART adherence.
Conclusions: A high proportion of HIV-infected adolescents studied had excellent ART adherence and
virologic suppression, with male adolescents at higher risk of suboptimal adherence than females. Further
research to investigate how gender relates to suboptimal adherence may aid in the design of targeted
intervention strategies.
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Objective: Little is known about factors associated with suboptimal antiretroviral treatment 
(ART) adherence among adolescents in Sub-Saharan Africa. Our objective was to determine 
the level of ART adherence and predictors of non-adherence among human immunodeficiency 
virus (HIV)-infected adolescents at the Botswana-Baylor Children’s Clinical Centre of Excel-
lence in Gaborone, Botswana.
Methods: In a cross-sectional study, 82 HIV-infected adolescents receiving ART and their 
caregivers were administered a structured questionnaire. The patient’s clinical information was 
retrieved from medical records. Outcome measures included excellent pill count ART adher-
ence (.95%) and virologic suppression (HIV viral load ,400 copies/mL). Multivariate logistic 
regression analysis was performed to identify independent predictors of ART non-adherence. 
Results: The overall median (interquartile range) ART adherence was 99% (96.5–100) (N = 82). 
Seventy-six percent of adolescents had excellent pill count ART adherence levels and 94% 
achieved virologic suppression. Male adolescents made up 65% of the non-adherent group 
(P = 0.02). Those who displayed suboptimal ART adherence were more likely to report having 
ever missed ART doses due to failure to pick up medication at the pharmacy (30.0% versus 
9.7%, P = 0.03). In the multivariate logistic regression model, male sex (odds ratio [OR] 3.29, 
95% confidence interval [CI] 1.13–9.54; P = 0.03) was the only factor which was independently 
associated with suboptimal ART adherence. 
Conclusions: A high proportion of HIV-infected adolescents studied had excellent ART adher-
ence and virologic suppression, with male adolescents at higher risk of suboptimal adherence 
than females. Further research to investigate how sex relates to suboptimal adherence may aid 
in the design of targeted intervention strategies.
Keywords: HIV/AIDS, ART adherence, adolescents, barriers, Botswana
Introduction
In 2011, an estimated 330,000 children under the age of 15 years were newly infected 
with human immunodeficiency virus (HIV), contributing to an estimated 3.3 million 
children living with HIV worldwide. Over 90% of these children live in  Sub-Saharan 
Africa and less than a third of them have access to antiretroviral treatment (ART).1 In 
2009 in Botswana, 19,125 children aged 0–14 years were living with HIV infection.2,3 
Access to ART has significantly reduced mortality among children with HIV. However, 
children and adolescents experience unique challenges to sustained treatment adherence, 
including the need for support from caregivers and providers, issues surrounding the dis-
closure of HIV status, their rebellious nature, and management of adverse events.4–13
The few available data from sub-Saharan Africa have shown that, compared with 
adults, adolescents were less adherent to ART, had lower rates of virologic  suppression, 
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and had a higher rate of virologic rebound after initial sup-
pression.9–12 However, specific data on possible barriers for 
poor ART adherence were not reported. The objective of the 
present study, therefore, was to investigate ART adherence 
and the factors associated with suboptimal adherence among 
HIV-infected adolescents at the Botswana-Baylor Children’s 
Clinical Centre of Excellence (BBCCCOE).
Methods
We conducted a cross-sectional study of HIV-infected 
adolescents between August 2010 and March 2011 at the 
BBCCCOE in Gaborone, Botswana. BBCCCOE is a com-
prehensive HIV/AIDS treatment care center based at Princess 
Marina Hospital, the main referral hospital in Gaborone. At 
this clinical setting, informal one-on-one adherence education 
and counseling is provided to all patients during routine care. 
Patients and families found to have adherence challenges are 
given intensified counseling with the head nurse, clinical 
psychologist, or social worker. A support group is available 
for adolescents who are at least 13 years of age and who 
know their HIV status. Using purposive sampling, adoles-
cents aged 13 to 18 years of age who had been on ART for 
a period longer than 6 months were eligible to participate in 
the study. The cut-off point of 6 months was chosen to allow 
us to use viral load as an endpoint, because it can take up to 
6 months for individuals to achieve virologic suppression 
on ART.14 Because all study subjects were minors, consent 
from parents/guardians was required along with participant 
assent.15
A standardized self-administered questionnaire adapted 
from the AIDS Clinical Trials Group16 was used to collect 
socio-demographic information as well as other explana-
tory variables (HIV status of caregivers, the adolescent’s 
relationship with caregivers, and the presence or absence 
of a family and friend network support, among others). 
In addition, electronic medical record system was used to 
retrieve clinical and laboratory data. Pill count data were 
used to assess adherence to ART over the previous month, 
as medication is dispensed on a monthly basis. The propor-
tion of adherence was calculated as follows: the numerator 
was the total number of pills provided at the previous visit 
minus the number of pills remaining, and the denominator 
was the number of pills required per day times the number 
of days since the last visit; this ratio was multiplied by 100. 
Adherence to ART was considered excellent when the pill 
count was $95% of prescribed doses.17
Sociodemographic and clinical characteristics of the 
participants as well as adherence rates were compared using 
Chi-square or Fisher’s exact test for categorical variables. 
Wilcoxon’s rank-sum test was used for continuous variables. 
Logistic regression was performed to identify factors asso-
ciated with adherence. Variables in the univariate analysis 
with a P , 0.1, as well as selected factors hypothesized to 
be confounding factors (a factor associated with the predic-
tor and outcome but not in the causal path), such as age 
above the median, CD4+ T-cell count, and World Health 
Organisation (WHO) clinical stage, were included in the 
multivariate logistic regression model. All P-values reported 
are two-tailed. A P-value ,0.05 was considered significant. 
Data were entered in Epi Info 2003 (US Centers for Disease 
Control, Atlanta, GA, USA) and analyzed using Statistical 
Package STATA release 11.2 (STATA Corporation, College 
Station, TX, USA).
Ethical approvals were obtained from the follow-
ing ethical review committees: the Health Research and 
Development Division, Ministry of Health, Botswana; 
the Human Research Ethics Committee, University of the 
Witwatersrand, Johannesburg, South Africa; and the Insti-
tutional Review Board for Human Subject Research, Baylor 
College of Medicine, Houston, TX, USA.
Results
Of 400 adolescents informed about the study, only 82 consented 
and enrolled. The most prevalent (.90%) reasons for not 
enrolling in the study were nonavailability of a caregiver at the 
clinic and lack of interest. 40.2% of the adolescents were on 
a non-nucleoside reverse transcriptase (NNRTI, efavirenz or 
nevirapine)-based ART regimen and 58.5% were on a protease 
inhibitor (lopinavir-boosted ritonavir (LPV/r))-based ART reg-
imen. But only 13 of 82 (16%) adolescents in this study were 
on a second-line ART regimen ([LPV/r-based ART: n = 12] 
or [raltegravir-based ART: n = 1]). The main demographics, 
clinical and laboratory data, as well as factors for nonadher-
ence documented at enrollment, are shown in Table 1. Overall, 
75.6% of adolescents had excellent (.95%) pill count ART 
adherence levels, and all but 5 (94%) had virologic suppression 
to less than 400 copies/mL. Male adolescents made up 65% of 
the non-adherent group, but only 35.5% of the adherent group 
(P = 0.02). Study participants who self-reported suboptimal 
ART adherence were more likely to report having ever missed 
ART doses due to failure to pick up medication at the pharmacy 
(30.0% versus 9.7%, P = 0.03). In univariate analysis, male sex 
(odds ratio [OR] 3.38, 95% confidence interval [CI] 1.17–9.71; 
P = 0.02) and failure to refill ART medicine at the pharmacy 
(OR 4.31, 95% CI 1.19–15.53; P = 0.03) were significantly 
associated with suboptimal ART adherence. In the multivariate 
Patient Preference and Adherence 2013:7
Table 1 Clinical and socio-demographics at enrolment by pill count ARt adherence threshold of 95%
Variables Number  
(N = 82)
Adherent ($95%) 
(62, 75.6%)
Nonadherent (,95%) 
(20, 24.4%)
P- value
Age, median (iQR) 15 (14–16) 15 (14–16) 15 (14–16) 0.43
male sex, n (%) 35 (42.7) 22 (35.5) 13 (65.0) 0.02
WHo Stage, n (%) 
 i 
 ii 
 iii 
 iV
12 (14.6) 
11 (13.4) 
34 (41.5) 
25 (30.5)
9 (14.5) 
9 (14.5) 
28 (45.2) 
16 (25.8)
3 (15.0) 
2 (10.0) 
6 (30.0) 
9 (45.0)
0.42 
 
 
Cd4 t-cell count, median (iQR) 759 (575–946) 746 (528–1011) 779 (628–886) 0.70
Viral load ,400 copies/mL, n (%) 77 (93.9) 59 (95.2) 18 (90.0) 0.59
duration on ARt in years, median (iQR) 5 (3–6) 5 (3–6) 5 (3–6) 0.96
duration on ARt .5 years, n (%) 37 (45.1) 27 (43.5) 10 (50.0) 0.80
ARt regiment, n (%) 
 nnRti-based 
 Pi-based 
 other
33 (40.2) 
48 (58.5) 
1 (1.3)
24 (38.7) 
37 (59.7) 
1 (1.6)
9 (45.0) 
11 (55.0) 
0 (0.0)
0.84 
 
Female caregiver, n (%) 73 (90.1) 55 (88.7) 18 (94.7) 0.67
Biologic relation with caregiver, n (%) 45 (55.6) 35 (56.4) 10 (52.6) 0.80
Caregiver HiV status known, n (%) 52 (64.2) 39 (62.9) 13 (68.4) 0.79
Caregiver with HiV+, n (%) 36 (73.5) 27 (71.0) 9 (81.8) 0.70
Family support network, n (%)
  do you discuss with parents/caregiver about  
the importance of adherence to ARt? (yes)
63 (76.8) 48 (77.4) 15 (75.0) 0.82
Perception (outcome expectancy), n (%)
  do you believe the pills you are taking are  
going to make you a healthy person? (yes)
75 (91.5) 57 (91.9) 18 (90.0) 0.79
drug toxicity, n (%)
  Do you feel fine after taking your pills? (yes) 75 (91.5) 57 (91.9) 18 (90.0) 0.79
Pharmacy no refill, n (%)
  Have you ever missed a dose because  
you, your parents or caregiver did not  
collect the pills at the pharmacy? (yes)
12 (14.8) 6 (9.7) 6 (30.0) 0.03
Abbreviations: iQR, interquartile range; ARt, antiretroviral treatment; WHo, World Health organisation; nnRti, non-nucleoside reverse transcriptase; Pi, protease 
inhibitor; HIV, human immunodeficiency virus. 
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analysis, male sex (OR 3.29, 95% CI 1.13–9.54; P = 0.03) 
was the only factor which was independently and significantly 
associated with suboptimal ART adherence (Table 2).
Discussion
This study found that 75.6% of adolescents with a median 
ART duration of 5 years had excellent (.95%) ART adher-
ence, with an overall mean of 96.4%. These findings are 
important because there is emerging concern that there are 
specific challenges for adolescent patients, such as rebel-
liousness and potentially higher rates of mortality, when 
compared to other populations.18
Although some studies have shown similar high rates of 
ART adherence among HIV-infected adolescents,6 a lower 
rate of adherence among HIV-infected adolescents has been 
reported more often,5–7,9 and expectations have been that adher-
ence will diminish over time. In 2009, a review of studies on 
ART adherence and intervention among HIV-infected youths 
(13–24 years old) reported an overall rate of  adherence ranging 
from 28.3% to 69.8%.6 The high proportion of HIV-infected 
adolescents with excellent pill count ART adherence and 
virologic suppression documented in our study is encouraging 
and demonstrates that excellent treatment outcomes can be 
achieved in HIV-infected adolescents in this setting. Interest-
ingly, analysis of the barriers to adherence in this study revealed 
that male sex was an independent predictor of nonadherence to 
ART in our cohort. Our data are supported by a study of 804 
children and adolescents between the ages of 3 and 16 years at 
initiation on NNRTI-based treatment at the same clinical site 
by Lowenthal et al,19 who reported that patients of both sexes 
were more likely to have had virologic failure on nevirapine-
based treatment than on efavirenz-based treatment, but failure 
rates on both regimens were higher among males than among 
females, with males on nevirapine having the highest failure 
rates. The findings of our study suggest that the sex-specific 
differences in outcomes observed by Lowenthal et al may be 
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Table 2 univariate and multivariate logistic regression model of factors associated with ARt adherence ,95%
Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age above median 0.73 (0.24–2.15) 0.56 0.87 (0.27–2.77) 0.81
male sex 3.38 (1.17–9.71) 0.02 3.29 (1.13–9.54) 0.03
WHo stage iii and iV (versus i and ii) 1.23 (0.39–3.88) 0.73 1.02 (0.30–3.47) 0.97
Pi-based versus nnRti-based regimen 0.79 (0.28–2.20) 0.65
Cd4 above median 1.30 (0.47–3.59) 0.61 1.18 (0.40–3.44) 0.76
VL ,400 copies/mL 0.46 (0.07–2.95) 0.40
Biologic relation with caregiver 0.86 (0.30–2.40) 0.77
Caregiver who is HiV+ 1.83 (0.34–9.88) 0.48
Caregiver with HiV status known 1.28 (0.43–3.82) 0.66
Having a support network 0.87 (0.27–2.83) 0.82
Positive outcome expectancy 0.79 (0.14–4.42) 0.79
never experience ARt side  
effects/toxicity
0.79 (0.14–4.42) 0.79
Abbreviations: Pi, protease inhibitor; nnRti, non-nucleoside reverse transcriptase; VL, viral load; ARt, antiretroviral treatment; WHo, World 
Health Organisation; CI, confidence interval; OR, odds ratio; HIV, human immunodeficiency virus.
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explained by worse adherence in males. Furthermore, there 
is a growing body of evidence indicating that adult men face 
important challenges in accessing HIV services as often as 
their female counterparts and also experience worse treatment 
outcomes, including mortality.18,20,21
The fact that patients fail to pick up ART medications at 
the pharmacy at all suggests that structural barriers (eg, lack 
of transport money to access the clinic or other factors)22,23 
may play a role in this study population. In addition, because 
even one incidence of not obtaining a refill on time is strongly 
associated with current pill count adherence suggests that 
there are long-term concerns (forgetfulness, not making their 
medicines a priority, chaotic households, and so forth) for 
those who ever miss a refill date. Essentially, if a patient has 
ever missed a refill, he or she is more likely to miss doses 
now, suggesting a long-term increased risk of suboptimal 
adherence even in the absence of ongoing refill problems. 
Although our results are informative and preliminary and 
need further confirmatory studies, they suggest that male 
adolescents, and those having a history of ever failing to refill 
ART at the pharmacy in this setting, may benefit from more 
intensive monitoring and adherence interventions.24
Our study may be limited by selection bias and findings 
may not be generalizable to other settings in Africa. The BBC-
CCOE site has better resources than many clinics in resource-
limited settings, including a supportive environment that aims 
to equip teenagers with the appropriate skills to enable them 
to face the challenges of adolescence; this may in part explain 
the documented high ART adherence here. Furthermore, we 
recruited from among patients with an available caregiver at 
the clinic. Those who did not have an available caregiver, as 
well as those not able to consent due to lack of interest or 
other reasons, were less likely to be included but may have 
been poorly adherent to their ART regimen.
Conclusions
This study found that a high proportion of HIV-infected ado-
lescents aged 13 to 18 years who are attending the BBCCCOE 
for HIV care are highly adherent to their ART medication 
regimens and achieved virologic suppression. Being male and 
having a history of failure to refill ART at a pharmacy were 
significant risk factors for suboptimal adherence among HIV/
AIDS-infected adolescents in this study population. Our data 
call for a prospective evaluation in a larger study to confirm 
our findings and investigate further why males are more likely 
to have suboptimal adherence than females; this may improve 
the design of targeted intervention strategies in this setting.
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